Antibody-drug conjugates (ADCs): all 1,111 studies that test it

Page 4 of 12. Open to participants first (502), then studies with results posted, then the rest; newest registration first within each.

• Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder CancerRecruitingNCT06394570Phase 1/2
• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)RecruitingNCT06393374Phase 3
• Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALLRecruitingNCT06387121Phase 2
• RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric CancerNot yet recruitingNCT06385873Phase 2
• Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 FusionRecruitingNCT06383884Phase 2
• To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2RecruitingNCT06378242Phase 1/2
• A Study of BV-AVD in People With Bulky Hodgkin LymphomaRecruitingNCT06377566Phase 2
• A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)RecruitingNCT06362252Phase 1/2
• Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsRecruitingNCT06357533Phase 3
• Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial CancerRecruitingNCT06356155Phase 2
• Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT06350097Phase 3
• Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryRecruitingNCT06348134Phase 2
• Investigator Grant (IG) 2022 27746RecruitingNCT06341478Not applicable
• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)RecruitingNCT06330064Phase 1/2
• Sacituzumab Govitecan for Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06329869Phase 2
• A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)RecruitingNCT06312176Phase 3
• A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)RecruitingNCT06312137Phase 3
• Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)RecruitingNCT06311214Phase 2
• Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary CarcinomaRecruitingNCT06302569Phase 2
• Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast CancerRecruitingNCT06299852Not applicable
• Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXdRecruitingNCT06298084Phase 1/2
• Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical TrialRecruitingNCT06278870Phase 3
• Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBCRecruitingNCT06263543Phase 2
• Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual DiseaseRecruitingNCT06253650Phase 2
• Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain MetastasesEnrolling by invitationNCT06250777Phase 2
• A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial TumorsRecruitingNCT06248515Phase 2
• Sacituzumab Govitecan in Metastatic Colorectal CancerRecruitingNCT06243393Phase 2/3
• HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab GovitecanRecruitingNCT06236269Phase 2
• Sacituzumab govitEcan in THYroid CancersRecruitingNCT06235216Phase 2
• A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic CancerNot yet recruitingNCT06233864Phase 2
• Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 OverexpressionNot yet recruitingNCT06227325Phase 2
• Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate CancerRecruitingNCT06227156Phase 2
• DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyRecruitingNCT06221748Phase 2/3
• A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical SurgeryRecruitingNCT06210490Phase 2
• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerRecruitingNCT06203210Phase 3
• BV-AVD-R Treatment Children Hodgkin's LymphomaEnrolling by invitationNCT06201507Phase 2
• CD30 Imaging in Diffuse Large B-cell LymphomaNot yet recruitingNCT06186986Phase 3
• A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial CarcinomaRecruitingNCT06178601Phase 2
• DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast CancerRecruitingNCT06178159Phase 2
• Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL PatientsRecruitingNCT06176729Phase 2
• DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEsRecruitingNCT06176261Phase 2
• A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)RecruitingNCT06174987Phase 3
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06172478Phase 2
• Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)RecruitingNCT06170788Phase 3
• Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...RecruitingNCT06161532Phase 2
• A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical CancerRecruitingNCT06155396Phase 2
• Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT06155383Phase 2
• Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2
• Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP TherapyRecruitingNCT06125834Phase 2
• Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the PenisRecruitingNCT06104618Phase 2
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)RecruitingNCT06103864Phase 3
• Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric CancerRecruitingNCT06085755Phase 1/2
• Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerRecruitingNCT06081959Phase 3
• Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric CancerRecruitingNCT06078982Phase 1
• A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder CancerRecruitingNCT06074484Phase 2
• A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell LymphomaRecruitingNCT06071871Phase 2
• Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard TherapyRecruitingNCT06065371Phase 1
• RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical CancerRecruitingNCT06063018Phase 2
• Trastuzumab Deruxtecan (T-DXd) for People With Brain CancerRecruitingNCT06058988Phase 2
• Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationRecruitingNCT06043674Phase 2
• Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)RecruitingNCT06041503Phase 2
• Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial CancerRecruitingNCT06040970Phase 1/2
• A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid TumorsRecruitingNCT06016062Phase 1/2
• Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06015880Phase 1
• Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid TumorsRecruitingNCT06014658Phase 1/2
• Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast CancerNot yet recruitingNCT06000033Phase 2
• RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder CancerNot yet recruitingNCT05996952Phase 2
• A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT05991388Phase 2/3
• Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGCRecruitingNCT05982834Phase 1/2
• Basket Study for Oligo-metastatic Breast CancerRecruitingNCT05982678Phase 2
• RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBCRecruitingNCT05979740Phase 2
• Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal CancerRecruitingNCT05965479Phase 2
• RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 ExpressionRecruitingNCT05957757Phase 2
• T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low PatientsNot yet recruitingNCT05953168Phase 2
• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerRecruitingNCT05950945Phase 3
• RC48-ADC in Combination With Gemcitabine in High Risk NMIBC SubjectsRecruitingNCT05943379Phase 2
• Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALLRecruitingNCT05940961Phase 2
• RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 ExpressionRecruitingNCT05940896Phase 1
• Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05940051Phase 2
• Efficacy and Safety of Disitamab Vedotin Combined With SintilimabNot yet recruitingNCT05928897Phase 2
• Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple MyelomaRecruitingNCT05922501Phase 2
• A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial CarcinomaRecruitingNCT05917158Phase 2
• Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC PatientsRecruitingNCT05912816Phase 2
• Disitamab Vedotin Combined With Radiotherapy for Bladder PreservationNot yet recruitingNCT05912205Phase 2
• Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)RecruitingNCT05904964Phase 3
• Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast CancerRecruitingNCT05900206Phase 2
• T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaRecruitingNCT05894824Phase 1/2
• An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and OlaparibRecruitingNCT05887609Phase 2
• Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)RecruitingNCT05879653Phase 2
• Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell LymphomaRecruitingNCT05868395Phase 2
• The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 ExpressionRecruitingNCT05861635Phase 4
• Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple MyelomaRecruitingNCT05853965Phase 1/2
• Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 AlterationsNot yet recruitingNCT05847764Phase 2
• Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple MyelomaRecruitingNCT05847569Phase 2
• Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingNCT05845450Phase 2
• A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical CancerRecruitingNCT05838521Phase 2
• Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)RecruitingNCT05837806Phase 2
• Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder CancerRecruitingNCT05833867Phase 1
• RC48-ADC in HER2-low Advanced Breast CancerRecruitingNCT05831878Not applicable
• TRUDI: TDXD+Durva in HER2+/Low IBCRecruitingNCT05795101Phase 2

← Antibody-drug conjugates (ADCs) overview